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Impaired barrier function in patients with house
dust mite–induced allergic rhinitis is accompanied
by decreased occludin and zonula occludens-1
expression
Brecht Steelant, MSc,a Ricard Farre, PhD,b Paulina Wawrzyniak, MSc,c Jochen Belmans, MSc,d Emily Dekimpe, MSc,a,e
Hanne Vanheel, PhD,b Laura Van Gerven, MD, PhD,a,e Inge Kortekaas Krohn, MSc,a Dominique M. A. Bullens, MD, PhD,d
Jan L. Ceuppens, MD, PhD,a Cezmi A. Akdis, MD,c Guy Boeckxstaens, MD, PhD,b Sven F. Seys, PhD,a and
Peter W. Hellings, MD, PhDa,e,f,g Leuven and Ghent, Belgium, Davos, Switzerland, and Amsterdam, The Netherlands
Background: Tight junction (TJ) defects have recently been
associated with asthma and chronic rhinosinusitis. The
expression, function, and regulation of nasal epithelial TJs
remain unknown in patients with allergic rhinitis (AR).
Objective: We investigated the expression, function, and
regulation of TJs in the nasal epithelium of patients with house
dust mite (HDM)–induced AR and in an HDM-induced murine
model of allergic airway disease.
Methods: Air-liquid interface cultures of primary nasal epithelial
cells of control subjects and patients with HDM-induced ARwere
used for measuring transepithelial resistance and passage to
fluorescein isothiocyanate–dextran 4 kDa (FD4). Ex vivo
transtissue resistance and FD4 permeability of nasal mucosal
explants were measured. TJ expression was evaluated by using
real-time quantitative PCR and immunofluorescence. In addition,
the effects of IL-4, IFN-g, andfluticasonepropionate (FP) on nasal
epithelial cells were investigated in vitro. An HDMmurine model
was used to study the effects of allergic inflammation and FP
treatment on transmucosal passage of FD4 in vivo.
Results: A decreased resistance in vitro and ex vivo was found in
patients with HDM-induced AR, with increased FD4
permeability and reduced occludin and zonula occludens-1
expression. AR symptoms correlated inversely with resistance in
patients with HDM-induced AR. In vitro IL-4 decreased
transepithelial resistance and increased FD4 permeability,
whereas IFN-g had no effect. FP prevented IL-4–induced
barrier dysfunction in vitro. In an HDM murine model FP
prevented the allergen-induced increased mucosal permeability.
Conclusion: We found impaired nasal epithelial barrier function
in patients with HDM-induced AR, with lower occludin and
zonula occludens-1 expression. IL-4 disrupted epithelial
integrity in vitro, and FP restored barrier function. Better
understanding of nasal barrier regulation might lead to a better
understanding and treatment of AR. (J Allergy Clin Immunol
2016;137:1043-53.)
Key words: Allergic rhinitis, tight junctions, fluticasone propionate,
IL-4, leak pathway, epithelial resistance, epithelial permeability
A critical role of the airway epithelium is forming a physical
barrier protecting the body from inhaled harmful substances. The
mucosal barrier is primarily determined by the integrity of
intercellular junctions through which epithelial cells are con-
nected to each other (ie, tight junctions [TJs], adherens junctions,
and desmosomes), ultimately sealing off the paracellular space.1
TJs form the most apical intercellular junction between epithelial
cells, providing functional polarity between the apical and baso-
lateral domains.2 TJs consist of different transmembrane proteins,
including occludin, tricellulin, the claudin family, and junctional
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ALI: Air-liquid interface
AR: Allergic rhinitis
FD4: Fluorescein isothiocyanate–dextran 4 kDa
FP: Fluticasone propionate
HDM: House dust mite
INS: Intranasal steroid
NEC: Nasal epithelial cell
RT-qPCR: Real-time quantitative PCR
TER: Transepithelial resistance
TJ: Tight junction
ZO: Zonula occludens
adhesion molecules.3 They form intercellular homodimers/
heterodimers between neighboring cells, limiting the paracellular
passage of macromolecules. Scaffold adaptor proteins, such as
cingulin and the zonula occludens (ZO) family, connect the
transmembrane proteins to the actin cytoskeleton. TJs are
involved in 2 transport pathways: pore and leak pathways.4 The
leak pathway is mainly regulated by occludin and ZO, allowing
limited passage of larger molecules, whereas the pore pathway
is a size- and charge-selective high-capacity route for ions, as
regulated by claudins.
Disturbed TJ function, expression, or both can lead to the
entrance of foreign pathogens, irritants, and allergens into the
organism.5 Multiple disorders, such as asthma,6 inflammatory
bowel disease,7 functional dyspepsia,8 and atopic dermatitis,9
have been linked to defective or altered TJ function. Recently,
impaired epithelial barrier function was found in patients with
chronic rhinosinusitis with or without nasal polyps,10 suggesting
changes in TJ arrangement in the sinonasal mucosa. Nevertheless,
the function, expression, and regulation of TJs have not been
investigated in patients with allergic rhinitis (AR).
AR is defined as an inflammation of the nasal mucosa resulting
from an IgE-mediated allergy to inhaled allergens.11 AR affects
30% of theWestern population and causes symptoms, such as nasal
obstruction, rhinorrhea, sneezing, and itchy nose.12 Despite the
available treatment options, such as intranasal steroids (INSs), anti-
histamines, or leukotriene receptor antagonists and immuno-
therapy,13,14 20% of patients with AR do not respond properly to
treatment, representing a therapeutic challenge with a large
socioeconomic burden.15-18 The reason for lackof response to treat-
ment ismultifactorial,with barrier dysfunction being one of the rea-
sons. A dysfunctional epithelial barrier might give rise to enhanced
uptake of allergens and exogenous particles, leading tomore activa-
tion ofmast cells and nerve fibers.5,19 Therefore it is of great interest
to study epithelial barrier and TJ function in patients with AR.
This study aimed at exploring the function, expression, and
regulation of TJs in the nasal epithelium of patients with house
dust mite (HDM)–induced AR. Using human air-liquid interface
(ALI) cultures of primary nasal epithelial cells (NECs), mucosal
explants, and an HDM-induced murine model of allergic airway
disease, we demonstrate an impaired barrier in patients with AR
and a barrier-correcting effect of fluticasone propionate (FP). FP
restored barrier integrity, which might be associated with
promotion of expression of occludin and ZO-1.
METHODS
Patients
For in vitro analyses, NECs were isolated from the inferior turbinates of
control subjects (n 5 16) and steroid-naive patients with HDM-induced AR
(n 5 9) during aesthetic and/or functional rhinoplasty. Control subjects
were nonsmokers, did not report any nasal symptoms suggestive of AR, and
did not have a history of AR or rhinosinusitis. All included patients with
HDM-induced AR were symptomatic (>_2 nasal symptoms of AR) at the
time of inclusion, were nonsmoking nonasthmatic subjects, and did not
show any clinical sign of infection in the nose at time of surgery. Patient infor-
mation can be found in Table I.
Nasal biopsy specimens were taken from 10 healthy nonallergic control
subjects without any nasal symptoms and from 15 patients with HDM-induced
AR to evaluate epithelial barrier integrity at the mucosal explant level. Biopsy
specimens were taken 10 minutes after application of a spray with local
anesthesia (5% cocaine). Four nasal biopsy specimens were taken with a
Fokkens forceps. The biopsy specimens were kept on ice in saline for further
analysis. Patients’ demographics can be found in Table II.
The study protocol was approved by the local ethics committee of UZ
Leuven. The study was registered at clinicaltrial.gov (NCT02461797).
Evaluation of nasal symptoms
Patients participating in the mucosal explant study were symptomatic
(>_2 nasal symptoms of AR) and were asked to mark the typical symptoms of
AR on a visual analog scale (score, 0-10). The major symptom was selected
based on the highest score on a visual analog scale.
Isolation and ALI cultures of primary NECs and
transepithelial resistance measurement
Inferior turbinates were used for isolation of NECs. A highly purified NEC
population was obtained, as reported previously.20 The full methodology is
provided in the Methods section in this article’s Online Repository at www.
jacionline.org.
Freshly isolated NECs were seeded on 0.4-mm, 0.33-cm2 polyester
Transwell inserts (Costar, Corning, NY) at a density of 105 cells per Transwell.
Medium was refreshed every other day. Once NECs grew to complete
confluence, the apical culture medium was removed to allow further cell
differentiation in the ALI. At day 21 in the ALI, epithelial integrity was
evaluated by using transepithelial resistance (TER) measurements with an
EVOM/Endohm (WPI, Sarasota, Fla). Cultures not building up sufficiently
(TER, <200 V 3 cm2) were not included in experiments (14%). TER was
measured in triplicate for each subject.
Paracellular flux measurements
Epithelial permeability as a surrogate marker of layer integrity was
measured by using fluorescein isothiocyanate–dextran 4kDa (FD4;
Sigma-Aldrich, St Louis, Mo). FD4 (2 mg/mL) was added apically to the
ALI cultures at day 21, and the fluorescein isothiocyanate intensity of
basolateral fluid was measured with a fluorescence reader (FLUOstar Omega;
BMG Labtech, Ortenberg, Germany). FD4 concentration was calculated and
is expressed in picomoles (pmols).
Cytokine stimulation experiments
NEC cultures from control subjects and patients with HDM-induced AR at
the ALI were stimulated at day 21 by adding different cytokines to the
basolateral compartment: 100 ng/mL IFN-g or 10 ng/mL IL-4 (R&DSystems,
Abingdon, United Kingdom). One hour before cytokine stimulation,
0.1 mmol/L FP (Sigma-Aldrich) or saline was added. TER and FD4
permeability was measured at 0, 24, 48, and 72 hours after stimulation. The
optimal concentration for the different stimulation experiments was based on
dose-response experiments in NEC cultures at the ALI.
Ussing chamber experiments for evaluation of
mucosal explant integrity
Nasal biopsy specimens were mounted in Ussing chambers
(Mussler Scientific Instruments, Aachen, Germany) with an opening of
0.017 cm2 to evaluate mucosal integrity ex vivo, as described previously.8 The
methodology can be found in the Methods section in this article’s Online
Repository.
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HDM-induced murine model of allergic airway
disease
Male C57Bl/6 mice (6-8 weeks) were obtained from Harlan (Horst, The
Netherlands) and kept under conventional conditions. Experimental
procedures were approved by the Ethical Committee for Animal Research
at KU Leuven. Mice were endonasally sensitized with 50 mL of HDM
extract (1 mg/mL; Greer Laboratories, Lenoir, NC) or 50 mL of saline at
day 0. From days 7 to 11, mice were endonasally challenged with 50 mL
of HDM extract (10 mg/mL) or 50 mL of saline. One hour before each
challenge, mice were administered endonasally FP (0.3 mg/kg body
weight) or sham (saline/10% dimethyl sulfoxide). One, 24, or 72 hours
after the last HDM challenge, 20 mL of FD4 (50 mg/mL) was applied
endonasally, allowing evaluation of nasal mucosal permeability. One hour
after FD4 application, mice were killed with intraperitoneal injection of
Nembutal (Ceva, Brussels, Belgium). Serum and the nasal mucosa were
collected. Bronchoalveolar lavage was performed, as previously
described.21 FD4 levels were determined in the serum by using a
fluorescence reader (FLUOstar Omega).
Real-time quantitative PCR for TJ genes
The methods for mRNA isolation and real-time quantitative PCR
(RT-qPCR) have been reported previously.22,23We chose to evaluate occludin,
ZO-1, claudin-1, and claudin-4 expression based on a literature search.10,24
Details and primer sequences can be found in the Methods section and
Table E1 in this article’s Online Repository at www.jacionline.org.
Immunofluorescence staining of TJs
See the Methods section in this article’s Online Repository for a detailed
description of immunofluorescence staining of TJs in ALI cultures and nasal
biopsy specimens. Immunofluorescence stainingswere performed on at least 8
paraffin slices (5 mm) of 8 healthy control subjects and 9 patients with
HDM-induced AR. Analysis of TJ immunofluorescence intensity was
performed in a blinded manner.
Statistical analysis
Data were analyzed with GraphPad Prism 5 software (GraphPad
Software, La Jolla, Calif). Differences between groups were analyzed by
using the 2-tailed unpaired t test or Mann-Whitney U test. Data are
presented as means 6 SDs or medians (interquartile ranges). One-way
ANOVAor the Kruskal-Wallis test with post hoc analysis was used to compare
multiple groups. Categorical values were compared by using the Fisher exact
test. Pearson r or Spearman r measurements were used to determine
correlations. Values were considered significantly different at a P value of
less than .05.
RESULTS
Ex vivo disturbed barrier function in nasal biopsy
specimens of patients with HDM-induced AR
We first evaluated epithelial barrier function at the mucosal
level in symptomatic patients with HDM-induced AR without
treatment (n5 9) and control subjects (n5 10). For this purpose,
nasal biopsy specimens were taken, and mucosal integrity was
evaluated in Ussing chambers. Nasal biopsy specimens of
patients with HDM-induced AR showed significantly lower
transtissue resistance compared with those of control subjects
(P < .05; Fig 1, A), with a higher transmucosal FD4 passage
(P < .05; Fig 1, B). Transtissue resistance and FD4 passage
correlated inversely, both in control subjects (P <.01) and patients
with HDM-induced AR (P < .001; Fig 1, C).
In patients with HDM-induced AR, the visual analog scale for
major symptoms correlated inversely with transtissue resistance
(P < .05; Fig 1, D), which was not found in control subjects
(P 5 .14; Fig 1, D).
In view of the ex vivo evidence for a disrupted epithelial barrier
in patients with HDM-induced AR, we investigated the
expression of the TJ network. Although more than 60 genes are
associated with junctional complexes, we focused on the
expression of claudin-1, claudin-4, occludin, and ZO-1.
RT-qPCR revealed significantly lower ZO-1 (P < .05) and
occludin mRNA (P < .05) expression in patients with
HDM-induced AR compared with that in control subjects
(Fig 1, E and F, respectively). No difference in mRNA expression
was found for claudin-1 (P 5 .84) and claudin-4 (P 5 .95)
between patients with HDM-induced AR and control subjects.
Immunofluorescence staining showed a relatively weak
arrangement of occludin and ZO-1 in biopsy specimens of
patients with HDM-induced AR compared with control subjects
(Fig 1,G). Quantification of mean occludin fluorescence intensity
showed a trend toward lower intensity of occludin in patients with
HDM-induced AR compared with control subjects without
reaching significance (6.4 3 108 vs 1.1 3 109, P 5 .18).
In vitro impaired nasal epithelial barrier function in
patients with HDM-induced AR
Next, we studied nasal epithelial integrity in vitro in patients
with HDM-induced AR and control subjects. Therefore NECs
were cultured at the ALI. After 21 days, TER of NEC cultures
from patients with HDM-induced AR was significantly lower
compared with that of control subjects (P < .01; Fig 2, A).
Paracellular flux of FD4 across the NEC monolayer showed a
significantly increased passage of FD4 in ALI cultures of patients
with HDM-induced AR (P < .001; Fig 2, B). Moreover, TER
negatively correlated with FD4 passage, both in NEC cultures
TABLE I. Patients’ demographic information for in vitro cell
work
Control subjects Patients with HDM-induced AR P value
No. 16 9 NA
Age (y) 37 6 18 31 6 13 .43
Male sex 56 67 .69
Smoking 0 0 NA
INS use 0 0 NA
Asthma 0 0 NA
HDM allergy 0 100 NA
NA, Not applicable.
TABLE II. Patients’ demographic information for ex vivo study
Control
subjects
Patients with
HDM-induced AR
P
value
No. 10 15 NA
Age (y) 29 (25-33) 24 (21-30) .14
Male sex 30 29 NA
Smoking (no.) 0 0 NA
INS use (no.) 0 6 NA
Mometasone furoate 0 3 NA
Fluticasone furoate 0 3 NA
Asthma (no.) 0 0 NA
HDM allergy (no.) 0 15 NA
NA, Not applicable.
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FIG 1. Impairedmucosal barrier function ex vivo in patients with HDM-induced AR. Nasal biopsy specimens
were isolated from control subjects and patients with HDM-induced AR for evaluation of mucosal integrity
in Ussing chambers. A, Transtissue resistance measured with Ussing chambers. B, FD4 epithelial
permeability. C, Transtissue resistance negatively correlated with FD4 passage in control subjects and
patients with HDM-induced AR. D-E, Lower mRNA expression of occludin and ZO-1 in patients with
HDM-induced AR compared with that in control subjects. Relative mRNA expression versus the
housekeeping genes encoding b-actin and b2-microglobulin is shown. F, Transtissue resistance negatively
correlated with visual analog scale scores for major symptoms in patients with HDM-induced AR.
G, Representative immunofluorescence staining for occludin and ZO-1 in 8 control subjects and 9 patients
with HDM-induced AR. *P < .05.
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FIG 2. Impaired NEC function in vitro in patients with HDM-induced AR. NECs were isolated from the
inferior turbinate and cultured in vitro. A, TER in ALI cultures after 21 days in patients with HDM-induced
AR and control subjects. B, FD4 passage in patients with HDM-induced AR and control subjects. C, TER
negatively correlated with FD4 passage in control subjects and patients with HDM-induced AR. D-E, Lower
mRNA expression of occludin and ZO-1 in patients with HDM-induced AR compared with control subjects.
Relative mRNA expression versus the housekeeping genes encoding b-actin and b2-microglobulin is
shown. F, Representative immunofluorescence staining showed less clear arrangement for occludin and
ZO-1 in patients with HDM-induced AR compared with that in control subjects. *P < .05, **P < .01, and
***P < .001.
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of control subjects (P < .05) and those of patients with
HDM-induced AR (P < .01; Fig 2, C).
Significantly lower mRNA expression was found in patients
with HDM-induced AR for ZO-1 (P <.05; Fig 2, D) and occludin
(P < .05; Fig 2, E) compared with that in control subjects. No
difference in mRNA expression was found for claudin-1
(P 5 .74) and claudin-4 (P 5 .33) between patients with
HDM-induced AR and control subjects.
Immunofluorescence staining of the TJ proteins occludin and
ZO-1 revealed an intact TJ layer in NEC cultures at the ALI of
control subjects, with strong expression of occludin and ZO-1
(Fig 2, F). However, the epithelial layer was disrupted in NEC
cultures at the ALI of patients with HDM-induced AR, with
less structured colocalization of TJs and lower expression of
occludin and ZO-1.
Taken together, the ex vivo and in vitro data showed an impaired
epithelial barrier function in patients with HDM-induced AR,
which is linked to reduced ZO-1 and occludin expression.
INSs restored barrier function ex vivo
INSs are first-line therapy in patients with AR. We compared
nasal mucosal explant function in patients with HDM-induced
AR using INSs (n5 6) and patients not using INSs (n5 9). Nasal
biopsy specimens of patients with HDM-induced AR using INSs
showed a significantly higher transtissue resistance (P <.05; Fig 3,
A) and a significantly lower FD4 passage (P < .05; Fig 3, B)
compared with values in patients with HDM-induced AR not
using INSs. Analysis of mRNA expression revealed a higher
occludin and ZO-1 expression in patients with HDM-induced
AR using INSs (Fig 3, C and D, respectively). Immunofluores-
cence staining for ZO-1 and occludin showed amore intact barrier
in patients taking INSs compared with that in patients with
HDM-induced AR not using INSs (Fig 3, E).
FP prevented IL-4–induced barrier disruption
Becausewe found ex vivo evidence for restored barrier function
in patients with HDM-induced AR using INSs, we investigated
how INSs, more specifically FP, and cytokines affect barrier
function. NEC cultures at the ALI of control subjects (n 5 5)
and patients with HDM-induced AR (n 5 4) were exposed in
duplicate to IL-4 (10 ng/mL) and IFN-g (100 ng/mL) at the
basolateral side. One hour before cytokine stimulation, FP
(0.1 mmol/L) or saline was added to the basolateral medium.
Incubation with IL-4 significantly reduced TER in cultures
from control subjects (Fig 4, A). When IL-4–supplemented
cultures were pretreated with FP, no decrease in TER was found
(Fig 4, A). FP alone increased TER after 72 hours (P < .05;
Fig 4, A). FD4 permeability was significantly increased after
72 hours of incubation with IL-4, whereas pretreatment of the
IL-4 cultures with FP significantly reduced FD4 permeability.
No significant decrease in FD4 permeability was found after FP
stimulation (Fig 4, B). Similar responses for IL-4, FP, and the
combination of IL-4 and FP were obtained in NEC cultures at
the ALI in patients with HDM-induced AR (n 5 4, see Fig E1
in this article’s Online Repository at www.jacionline.org). Treat-
ment with IFN-g did not influence the epithelial integrity or
permeability in NEC cultures at the ALI in control subjects and
patients with HDM-induced AR (Fig 4, C andD, and see Fig E1).
FP incubation for 72 hours upregulated mRNA expression of
occludin and ZO-1 (bothP <.05, see Fig E2 in this article’s Online
Repository at www.jacionline.org) compared with medium in
NEC cultures at the ALI in control subjects (n 5 5). FP did not
have an effect on mRNA expression of claudin-1 and claudin-4.
Next, a glucocorticoid receptor antagonist, RU-486, was used
to antagonize the effect of FP on barrier function. RU-486 alone
did not affect barrier integrity (Fig 5) and permeability (45 6 20
vs 356 12 pmol, P5 .38) in vitro in NEC cultures at the ALI in
control subjects. When RU-486 was added to NEC cultures at the
ALI 1 hour before FP, no increase in TER was measured (Fig 5).
Increased mucosal permeability after challenge
with HDM extract in a murine model of allergic
airway disease
In a last series of experiments, we used an HDM-induced
murine model of allergic airway disease25 to study mucosal
permeability after HDM sensitization and challenge and evalu-
ated the effect of FP treatment on mucosal permeability (Fig 6,
A). A significantly higher FD4 passage was found in sham/
HDM mice 1 and 24 hours after the last HDM challenge (Fig 6,
B) compared with sham/saline mice. FP reduced FD4 passage
to the blood in HDM-challenged mice 1 and 24 h after the last
challenge. FP alone (without HDM challenge) did not have a
significant effect on FD4 passage. No differences between the 4
groups with regard to FD4 passage were found 72 hours after
the last HDM challenge (Fig 6, B). To conclude, FP prevented
HDM-induced enhancement of FD4 passage in a murine model
of HDM-induced allergic airway inflammation.
DISCUSSION
Our study demonstrates impaired epithelial barrier function in
patients with HDM-induced AR. A lower epithelial integrity
together with an increased permeability and altered occludin and
ZO-1 expression was found in patients with HDM-induced AR.
First-line treatment with INSs restored mucosal integrity. FP
restored IL-4–induced impairment of epithelial barrier function
and resulted in upregulation of occludin and ZO-1 mRNA
expression.
AR is a prevalent inflammatory disorder of the nasal mucosa,
with the pathophysiologic mechanisms responsible for the
FIG 3. INSs restored barrier function ex vivo. Nasal biopsy specimens were isolated from patients
with HDM-induced AR using INSs (n 5 6) and not using INSs (n 5 9) for evaluation of mucosal integrity
in Ussing chambers. A, Transtissue resistance measured with Ussing chambers. B, FD4 epithelial
permeability. C-D, mRNA expression of occludin and ZO-1 was increased in patients with HDM-induced
AR using INSs. Relative mRNA expression versus the housekeeping genes encoding b-actin and
b2-microglobulin is shown. E, Representative immunofluorescence staining showed a restored
organization for occludin and ZO-1 in 3 patients with HDM-induced AR using INSs compared with 6 patients
with HDM-induced AR not using INSs. The data obtained for control subjects and patients with
HDM-induced AR using INSs are duplicated from Fig 1. *P < .05.
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severity of disease being only partly understood. In this regard the
role of the nasal epithelium in protecting subepithelial cells from
exposure to allergens remains unknown. Despite different
treatment options, 20% of patients with AR do not respond to
current treatment and remain symptomatic.15 In these patients we
are considering barrier dysfunction an important mechanism in
understanding their uncontrolled allergic inflammation. In view
of this, lower mRNA expression of occludin and ZO-1 was found
in patients with HDM-induced AR at both the cellular and tissue
levels. Therefore we conclude that the epithelial leak pathway is
involved in the pathology of AR. Less organized arrangement of
occludin and ZO-1 was found in patients with AR, suggesting that
defects in the leak pathway might facilitate the passage of
allergens and environmental proinflammatory agents through
the epithelial barrier. Interestingly, the strength of the leak
pathway is also reflected in the correlations between epithelial
integrity and FD4 permeability (Figs 1, C, and 2, C). Patients
with HDM-induced AR had a higher angle of the slope of
correlation, illustrating that an increased epithelial permeability,
which is found in patients with HDM-induced AR, might give
rise to activation of mast cells and afferent nerve fibers with
induction of inflammation and symptoms. Indeed, visual analog
scale scores for major symptoms correlated with transtissue
resistance, pointing to an important mechanism in the pathology
of AR.
Our data showing reduced expression of occludin and ZO-1 are
in line with observations in patients with chronic rhinosinusitis
with nasal polyps,10 as well as in asthmatic patients,6 patients with
atopic eczema,9 and patients with inflammatory bowel disease,7
in whom impaired epithelial TJ function is considered part of
the pathophysiology. In contrast to the leak pathway, the pore
pathway regulated by claudins does not seem to be of key
importance because no changes in claudin-1 and claudin-4
expression were observed in our study. Nevertheless, we cannot
exclude the possibility of other claudins being involved because
there are now more than 20 claudins identified26 without
precise insight into their contribution to the nasal mucosal barrier.
Indeed, we have checked the expression of claudin-2, the major
FIG 4. Regulation of epithelial barrier function in vitro by IL-4, IFN-g, and FP in healthy control subjects.
NECs were isolated from the inferior turbinates of control donors (n 5 5) and cultured in vitro to evaluate
the effect of proinflammatory cytokines and FP on NEC integrity. A, Effect of IL-4, FP, and IL-4 plus FP on
epithelial integrity, as measured with TER in duplicate. B, Effect of IL-4, FP, and IL-4 plus FP on FD4 epithelial
permeability. C, IFN-g did not influence TER measurements in control subjects. D, No effect of IFN-g on FD4
epithelial permeability in control subjects. *P < .05 and **P < .01.
FIG 5. RU-486 antagonized the effect of FP on epithelial integrity. NECs
were isolated from the inferior turbinates of control subjects (n 5 5) and
cultured in vitro to study the effect of FP and its antagonist, RU-486. Relative
TER changes in NEC cultures after stimulation. *P < .05 and **P < .01.
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pore-forming claudin in the intestine, in patients with
HDM-induced AR. There was no upregulation of claudin-2
compared with levels seen in control subjects (data not shown).
A dysfunctional nasal epithelial barrier in patients with AR has
been hypothesized to result in excessive allergen exposure and
stimulation of inflammatory cells27,28 on the one hand and clear-
ance of inflammatory mediators from the tissue to the lumen on
the other hand. Therefore restoring the epithelial barrier function
could limit the entrance of allergens. In the present study we
found that patients using INSs on a daily basis had a more intact
barrier than non–INS-treated patients, with upregulation of the TJ
proteins occludin and ZO-1 in the INS group. These data are fully
in line with those of Sekiyama et al,29 who showed that
budesonide, dexamethasone, and FP enhanced barrier function
of Calu-3 and 16HBE epithelial cells in vitro in a dose- and
time-dependent manner. Importantly, our data were obtained by
using primary NECs and are therefore more relevant than data
obtained by using epithelial cell lines, which have different
morphology, biochemical characteristics, and cellular responses
than freshly isolated NECs.30 Alternatively, activation of
Toll-like receptor 9 on airway epithelial cells by CpG-DNA can
also restore epithelial barrier integrity by affecting TJ expression,
highlighting the importance of restoration of epithelial barrier
function.31
To analyze the effect of inflammation on epithelial barrier
function, we used an in vitro NEC culture system from control
subjects and patients with HDM-induced AR to explore the
effects of proinflammatory cytokines: the TH2 cytokine IL-4
and the TH1 cytokine IFN-g. IL-4 decreased TER of freshly
isolated NECs with enhanced FD4 paracellular passage, as
described earlier by others,10,32 although the effect of IL-4 was
less pronounced in cultures from patients with HDM-induced
AR. The limited effect of IL-4 in patients with HDM-induced
AR is due to the already leaky epithelium, and therefore IL-4
cannot induce much more damage. The exact mechanism of
IL-4 on barrier (dys)function is thus far not fully known. It is
suggested that IL-4 might upregulate the expression of RhoA, a
small GTPase, which is a molecular switch for TJ homeostasis.
Upregulation of RhoA leads to disassembly of TJs and therefore
opening of the leak pathway.33 In contrast to IL-4, IFN-g did not
interfere with TER or FD4 passage in our in vitro NEC culture
system of control subjects and patients with HDM-induced AR.
Intriguingly, IFN-g has previously been reported to increase
epithelial permeability in primary bronchial epithelial cells10
and in T84 colonic epithelial cells,34 which was not confirmed
in our culture system by using freshly isolated NECs. This
discrepancy might be explained by the fact that airway epithelial
cells are primarily TH2 sensitive.
35 Indeed, Ahdieh et al36 have
shown that IFN-g enhanced lung epithelial wound healing,
illustrating the bivalent effect of IFN-g depending on the cells
used.
The in vitro NEC cultures were also used to study the effect of
one of the most commonly used INSs: FP. In NEC cultures FP
restored the IL-4–induced changes in nasal epithelial integrity,
which has not been reported before and allows a broader
interpretation of the action of INSs. FP treatment alone increased
epithelial integrity through upregulation of occludin and ZO-1.
Boivin et al37 have previously shown similar effects in Caco-2
intestinal epithelial cells stimulated with TNF-a.37 TNF-a has
previously been associated with increased intestinal epithelial
permeability, as measured with Ussing chambers, in patients
with colitis.38 When Caco-2 epithelial cells were treated with
FIG 6. HDM-inducedmurine model of allergic airway disease to study barrier function in vivo. A, Schematic
representation of the murine model. e.n., Endonasal. B, FD4 passage in the serum at different time points.
Data are presented as means 6 SEMs. *P < .05 and ***P < .001.
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glucocorticoids, the TNF-a–induced increase in TJ permeability
was reversed.37 On the other hand, IL-1b and IFN-g/TNF-a in
combination with dexamethasone did not result in decreased
permeability.39 This discrepancy might be explained by
differences in culture procedures and cytokine and/or
glucocorticoid concentrations.
Lastly, we evaluated in vivo whether HDM-sensitized mice
showed increased nasal permeability after HDM challenge.
Significantly higher serum FD4 levels were found in
HDM-sensitized animals 1 and 24 hours after the last allergen
challenge, whereas this difference was not present at 72 hours.
We hypothesize that the transient nature of this effect is related
to the proteolytic effect of Der p 1, a major allergen in the
HDM extract.40 It has been shown that Der p 1 can temporarily
break down TJs, which recover after removal of Der p 1 and
closing of the barrier.41 When HDM-challenged mice were
pretreated with FP, the FD4 passage was significantly lower 1
and 24 hours after the last HDM challenge compared with that
seen in sham-treated HDM mice. It still needs to be explored
whether the effect of FP on FD4 passage is orchestrated by the
anti-inflammatory effect or the barrier-promoting effect.
However, BAL eosinophil counts are significantly increased 24
and 72 hours, but not 1 hour, after the last challenge, suggesting
that the barrier effect comes first and is at least not enhanced by
the highly inflammatory environment at 72 hours (see Fig E3 in
this article’s Online Repository at www.jacionline.org).
In summary, an impaired epithelial barrier function is found in
patients with HDM-induced AR and is associated with lower
occludin and ZO-1 expression. IL-4 decreased epithelial barrier
function, which was prevented by FP. INSs restored epithelial
barrier integrity to similar levels found in control subjects and
might be related to upregulation of TJ proteins.
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ProfessorMark Jorissen (University Hospital Leuven) for providing part of the
nasal tissue for the isolation of epithelial cells and Joran Toth (TARGID,
Catholic University Leuven) for his important technical support. We also
thank the animal care takers for housing the mice during the experiments.
Key messages
d The epithelial barrier is impaired in patients with HDM-
induced AR.
d FP prevented IL-4–induced barrier dysfunction.
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METHODS
Isolation of primary NECs
Tissue was washed in sterile saline and enzymatically digested in 0.1%
Pronase (Protease XIV, Sigma) solution in DMEM-F12 culture medium
supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin, and 2%
Ultroser G (Pall Life Sciences, Zaventem, Belgium). After overnight incuba-
tion at 48Cwhile shaking, the protease reaction was stopped by the addition of
FCS (10%). Cells were washed in culture medium and pelleted by means of
centrifugation for 5 minutes at 100g. Cells were then resuspended in 10 mL of
culture medium and incubated in a plastic culture flask for 1 hour at 378C to
remove fibroblasts. The cell suspension was mixed with 2 3 107 prewashed
CD45 and CD15 magnetic beads (Dynabeads; Invitrogen, Merelbeke,
Belgium), and epithelial cells were purified by means of negative selection,
according to the manufacturer’s instructions. Cell purity was verified by using
cytospin preparations and was found to be 98% or greater.E1
Ussing chamber experiments for evaluation of
mucosal explant integrity
Nasal biopsy specimensweremounted inUssing chamberswith an opening
of 0.017 cm2 (Mussler Scientific Instruments, Aachen, Germany). Mucosal
and serosal compartments were filled with 3 mL of 10 mmol/L glucose in
Krebs-Ringer bicarbonate buffer. Solutions were kept at 378C and
continuously carbogenated with O2/CO2 (95/5%). Experiments were
performed in open-circuit conditions. Transtissue resistance was calculated
from the voltage deflections induced by bipolar constant-current pulses of
16mAevery 6 seconds with a duration of 200ms andwas recorded for 2 hours.
The average of all time points was taken, and results are presented asV3 cm.2
FD4 (1 mg/mL, Sigma-Aldrich) was added to the mucosal compartment.
Serosal samples were collected every 30 minutes over 2 hours to evaluate
the fluorescence intensity with a fluorescence reader (FLUOstar Omega).
Because a paracellular probe needs time to migrate to the serosal side, time
points of 0 and 30 minutes were left out of the analysis. The average of the
60-, 90-, and 120-minute time points of the biopsy specimens were taken,
and passage of FD4 is presented as picomoles.
RT-qPCR for TJ genes
At day 21 in ALI culture, primary NECs were collected from the Transwell
inserts with trypsin/EDTA and homogenized in lysis buffer from the Qiagen
Mini RNeasy Kit (Qiagen, Germantown, Md). Nasal mucosal biopsy
specimens were snap-frozen immediately after isolation. First-strand cDNA
was reverse transcribed with SuperScript II (Invitrogen, Carlsbad, Calif) with
1mg of total RNA, according to themanufacturer’s instructions. RT-qPCRwas
performed for claudin-1, claudin-4, occludin, and ZO-1 and the housekeeping
genes encoding b-actin (ACT2B) and b2-microglobulin. cDNA plasmid
standards, consisting of purified plasmid DNA specific for each target, were
used to quantify the target gene in the unknown samples, as previously
described.E2 Primer sequences can be found in Table E1.
Immunofluorescence staining of TJs
ALI cultures were cooled at 48C and washed with PBS before overnight
fixation with methanol at 2208C. Acetone was added for 1 minute, and ALI
cultures were air-dried. ALI cultures were hydrated in IMF buffer (0.1%
Triton X-100, 0.15 mol/L NaCl, 5 mmol/L EDTA, 20 mmol/L HEPES, and
0.02% NaN3) and incubated with mouse anti–ZO-1 (1:50, Invitrogen) and
rabbit anti-occludin (1:25, Invitrogen). Donkey anti-mouse Alexa Fluor 488
and donkey anti-rabbit Alexa Fluor 594 (both 1:1000, Invitrogen) were used
as secondary antibodies.
For immunofluorescence staining of nasal biopsy specimens,
paraffin-embedded tissue slides (5 mm) were subjected to antigen retrieval
in citrate buffer, pH 6 (Fluka). Antibodies used for immunofluorescence were
as follows: anti-occludin (rabbit, polyclonal, 1:100, 31721; Abcam,
Cambridge, United Kingdom), anti–ZO-1 (rabbit, polyclonal, 1/100,
61-7300, Invitrogen), and secondary antibody goat anti-rabbit Alexa
Fluor 488 (1/2000, Invitrogen). After staining, tissues were mounted with
49-6-diamidino-phenylindole dihydrochloride–containing mounting media.
Stained slides were stored at 2208C in the dark.
Confocal images were taken with either an LSM510 Meta Laser Scanning
microscope (Zeiss, Oberkochen, Germany) for the in vitro data or a Leica TCS
SPE confocal microscope (Leica Microsystems, Heerbrugg, Switzerland) for
explants. IMARIS software (Bitplane, Zurich, Switzerland) was used for
visualization of TJs.
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FIG E1. Regulation of epithelial barrier function in vitro by IL-4, IFN-g, and FP in patients with HDM-induced
AR. NECs were isolated from the inferior turbinates of patients with HDM-induced AR (n 5 5) and cultured
in vitro to evaluate the effect of proinflammatory cytokines and FP on NEC integrity. A, Effect of IL-4, FP, and
IL-4 plus FP on epithelial integrity, asmeasured with TER in duplicate. B, Effect of IL-4, FP, and IL-4 plus FP on
FD4 epithelial permeability. C-D, IFN-g did not affect TER and FD4 measurements. *P < .05 and **P < .01.
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FIG E2. FP upregulates mRNA expression of occludin and ZO-1 in primary NEC cultures from healthy
control subjects (n 5 5) when stimulated with FP for 72 hours. FP increased mRNA expression of occludin
(A) and ZO-1 (B) and had no effect on claudin-1 (C) and claudin-4 (D) expression. Relative mRNA expression
versus that of the housekeeping genes encoding b-actin and b2-microglobulin. Data are presented as
medians and interquartile ranges. *P < .05.
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FIG E3. Differential cell counts in bronchoalveolar lavage fluid in HDM-challenged mice. Eosinophilic
bronchoalveolar lavage counts were significantly lower 1 and 24 hours after the last challenge between
sham/HDM-challenged and FP/HDM-challenged mice. After 72 hours, no difference was found in
eosinophilic cell counts. *P < .05 and **P < .01, Kruskal-Wallis test with post hoc analysis.
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TABLE E1. Primer and probe sequences used for RT-qPCR
Forward primer Reverse primer Probe
b-Actin gga cat ccg caa aga cct gt ctc agg agg agc aat gat ctt gat ctg gcg gca cca cca tgt acc ct
b2-Microglobulin ctg aag ctg aca gca ttc gg ctt tgg agt acg ctg gat agc c aga tgt ctc gct ccg tgg cct tag c
Claudin-1 cca gtc aat gcc agg tac gaa t ata ggg cct tgg tgt tgg gt tca ggc tct ctt cac tgg ctg ggc
Claudin-4 ggt ctg ctc aca ctt gct gg gac gga ctt aac gtt cgc aga g tgg ctt tat ctc ctg act cac ggt gca
Occludin cca atg tcg agg agt ggg tta a ttg cca ttg gaa gag tat gcc ctg cag gca cac agg acg tgc c
ZO-1 gtg cct aaa gct att cct gtg agt c cta tgg aac tca gca cgc cc tgg cca cag ccc gag gca tat t
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